2 March 2015
ABOUT LEVULINIC ACID
DETAILS
is starting commercialization of its levulinic acid
thanks to its proprietary breakthrough technology.
Commercial-scale production will start in Summer 2015
in Caserta, Italy plant.
GFBiochemicals’ process technology
has been developed and tested at demo-scale since 2008.
The Caserta plant will scale-up to 8,000 MT/yr by 2017.
A new experienced management team
has been put in place to take GFBiochemicals forward.
Marcel van Berkel
is GFBiochemicals Chief Commercial Officer.
Van Berkel spent over 25 years at Solvay and DSM,
including in DSM’s Bio-based Products and Services division.
Davide Gremmi
joins as Chief Financial Officer.
Gremmi has over 20 years’ finance experience,
most recently at Chemtex Group.
Marcello Taglietti
is Chief Operating Officer
with over 20 years’ experience,
including at Air Products and Ashland.
Rudy Parton and Aris de Rijke
will spearhead R&D as
Director Technology & Applications Development and
Director Technology & Engineering.
Both have over 25 years’ experience at DSM and Shell.
Maxim Katinov,
CEO
“Our Team of experts has decades of experience in
innovation, production and business development.
We are now perfectly-placed to
bring biobased levulinic acid
to market and enable new applications that
will replace petro-based products.”
WWW.CHEMWINFO.COM BY KHUN PHICHAI
